DSG1

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

Retrieved on: 
Tuesday, December 14, 2021

The systemic therapies may have impacted clinical scores and DSG3 levels, both of which improved between screening and infusion.

Key Points: 
  • The systemic therapies may have impacted clinical scores and DSG3 levels, both of which improved between screening and infusion.
  • Additional data on the initial cohorts in the DesCAARTes trial are anticipated to be presented at medical meetings and/or scientific sessions in 2022.
  • Cabalettas DesCAARTes Phase 1 trial is an open-label, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes™ Trial in Patients with mPV

Retrieved on: 
Monday, November 1, 2021

PHILADELPHIA, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day clinical data from the third dose cohort using 500 million DSG3-CAART cells in the DesCAARTes™ Phase 1 clinical trial for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV).

Key Points: 
  • The rapid pace of the clinical trial has been possible due to the enthusiasm and engagement of patients, investigators and patient advocacy groups.
  • Dosing of patients in the fourth cohort at a treatment dose of 2.5 billion DSG3-CAART cells has been initiated.
  • The Company anticipates announcing 28-day safety data for the fourth dose cohort in the first quarter of 2022.
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

Retrieved on: 
Wednesday, August 18, 2021

PHILADELPHIA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced 28-day data from the second dose cohort, at the 100 million cell dose level, in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal-dominant pemphigus vulgaris (mPV).

Key Points: 
  • The DesCAARTes trial has initiated dosing of patients in the third cohort at a treatment dose of 500 million DSG3-CAART cells.
  • Absent DLTs in the third cohort, a fourth dose cohort using 2.5 billion cells is also anticipated to initiate dosing this year.
  • Cabaletta will continue to provide additional data on a cohort-by-cohort basis for the DesCAARTes trial as they become available.
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).